CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911

NDA FilingK-911Positive
AI Analysis

Summary

The FDA has accepted Kowa Pharmaceuticals America's NDA for K-911, a once-daily eye drop for treating intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Importance:6/10
Sentiment:
0.40
FDANDAGlaucomaOphthalmologyEye DropRegulatory
Related Companies

Read the original article

Published by Pharmaceutical Technology on August 28, 2026 8:56 AM

Read Original